SCHEMBL454623

SCHEMBL454623

[O]COP=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL6702975 0.67
SCHEMBL1656666 0.65
SCHEMBL3986191 0.64
SCHEMBL4024617 0.64
SCHEMBL10579621 0.64
SCHEMBL15704562 0.64
SCHEMBL377550 0.64
SCHEMBL8860058 0.64
SCHEMBL454624 0.64
SCHEMBL10427957 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7141559-B2 Glucocorticoid receptor ligands for the treatment of metabolic disorders KARO BIO AB (SE) 2006-11-28 US claimed
US-12012393-B2 Oxopiperazine derivatives Inthera Bioscience AG (CH) 2024-06-18 US disclosed
WO-2024119099-A1 GALLIUM-SALOPHEN ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2024-06-06 WO disclosed
EP-3544957-B1 DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE DANA FARBER CANCER INST INC (US) 2024-05-29 EP disclosed
US-20240158801-A1 STING DEPENDENT ADJUVANTS UNIVERSITY OF MIAMI 2024-05-16 US disclosed
EP-4358957-A1 (1H-PYRROLO[2,3-B]PYRIDIN-1-YL)PYRIMIDIN-2-YL-AMINO-PHENYL--ACRYLAMIDE INHIBITORS OF EGFR FOR USE IN THE TREATMENT OF BRAIN TUMORS Dana-Farber Cancer Institute, Inc. (US) 2024-05-01 EP disclosed
EP-3724178-B1 1-(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER Inthera Bioscience AG (CH) 2024-05-01 EP disclosed
EP-4359544-A1 STING DEPENDENT ADJUVANTS University of Miami (US) 2024-05-01 EP disclosed
EP-4351578-A1 SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE Stinginn Inc (US) 2024-04-17 EP disclosed
WO-2024073745-A1 INHIBITORS OF EGFR OR HER2 AND METHODS OF USE ARBELLA THERAPEUTICS, LLC (US) 2024-04-04 WO disclosed
EP-2340029-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2011-07-06 EP disclosed
WO-2011079231-A1 COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH GATEKEEPER PHARMACEUTICAL, INC. (US) 2011-06-30 WO disclosed
WO-2011022489-A2 (BIS) UREA AND (BIS) THIOUREA COMPOUNDS AS EPIGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-02-24 WO disclosed
WO-2011017519-A2 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-02-10 WO disclosed
WO-2010129053-A2 EGFR INHIBITORS AND METHODS OF TREATING DISORDERS DANA FARBER CANCER INSTITUTE (US) 2010-11-11 WO disclosed
WO-2010080712-A2 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS DANA FARBER CANCER INSTITUTE (US) 2010-07-15 WO disclosed
US-20100144608-A1 Macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. 2010-06-10 US disclosed
WO-2010030359-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARJMACEUTICALS, INC. (US) 2010-03-18 WO disclosed
US-7405218-B2 Isothiazole derivatives useful as anticancer agents PFIZER, INC. (US) 2008-07-29 US disclosed
US-20030149048-A1 Isothiazole derivatives useful as anticancer agents PFIZER INC. 2003-08-07 US disclosed